Stockscreener 앱 받기
7.54
0.46%
0.045
전일 마감가:
$7.585
열려 있는:
$7.69
하루 거래량:
23,752
Relative Volume:
0.22
시가총액:
$40.27M
수익:
$7.97M
순이익/손실:
$-75.74M
주가수익비율:
-0.3105
EPS:
-24.2853
순현금흐름:
$-85.33M
1주 성능:
-0.91%
1개월 성능:
-10.35%
6개월 성능:
-67.81%
1년 성능:
-36.51%
1일 변동 폭
$7.5246
$7.83
1주일 범위
$7.295
$7.9738
52주 변동 폭
$3.76
$46.80
Aligos Therapeutics Inc Stock (ALGS) Company Profile
명칭
Aligos Therapeutics Inc
전화
(800) 466-6059
주소
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
ALGS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALGS
Aligos Therapeutics Inc
|
7.5246 | 53.18M | 7.97M | -75.74M | -85.33M | -24.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
390.36 | 101.51B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.62 | 59.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
443.80 | 56.69B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
647.14 | 39.57B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
317.48 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-19 | 개시 | H.C. Wainwright | Buy |
| 2023-01-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-01-06 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-03-23 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-01-07 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-01-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-09-09 | 개시 | SVB Leerink | Outperform |
| 2021-05-17 | 재개 | Piper Sandler | Overweight |
| 2020-11-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-11-10 | 개시 | JP Morgan | Overweight |
| 2020-11-10 | 개시 | Jefferies | Buy |
| 2020-11-10 | 개시 | Piper Sandler | Overweight |
모두보기
Aligos Therapeutics Inc 주식(ALGS)의 최신 뉴스
Volatility clustering patterns for Aligos Therapeutics Inc.July 2025 Opening Moves & Low Risk Investment Opportunities - Newser
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
42,300 Shares: Aligos Therapeutics Awards New Employee Stock Options with 4-Year Vesting - Stock Titan
Why Aligos Therapeutics Inc. stock attracts strong analyst attentionQuarterly Earnings Report & Risk Managed Investment Strategies - Newser
Will Aligos Therapeutics Inc. stock recover after recent dropVolume Spike & Fast Exit Strategy with Risk Control - Newser
Aligos Therapeutics provides update on ALG-000184 for chronic hepatitis B - European AIDS Treatment Group
Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus - Zacks Investment Research
Custom watchlist performance reports with Aligos Therapeutics Inc.Market Weekly Review & Weekly High Conviction Ideas - Newser
Aligos Therapeutics Inc. stock momentum explainedWeekly Stock Recap & Free Community Consensus Stock Picks - Newser
Will Aligos Therapeutics Inc. continue its uptrendMarket Growth Summary & Capital Protection Trading Alerts - Newser
Aligos commences dosing in Phase II trial for chronic hepatitis B treatment - Yahoo Finance
How Efficient Is Aligos Therapeutics Inc. at Controlling Operating CostsJuly 2025 Macro Moves & High Accuracy Investment Signals - Newser
Can Aligos Therapeutics Inc. rally from current levelsPortfolio Gains Summary & Fast Gain Swing Trade Alerts - Newser
Does Aligos Therapeutics Inc. show high probability of rebound2025 Price Momentum & Consistent Growth Stock Picks - Newser
What indicators show strength in Aligos Therapeutics Inc.Volume Spike & Short-Term Trading Alerts - Newser
Best data tools to analyze Aligos Therapeutics Inc. stock2025 Year in Review & Momentum Based Trading Ideas - Newser
Moving Average Trends for Aligos Therapeutics Inc. Stock: What They IndicateBreakout Watch & Low Risk High Win Rate Picks - Newser
How to monitor Aligos Therapeutics Inc. with trend dashboardsJuly 2025 Action & Pattern Based Trade Signal System - Newser
Aligos begins dosing in phase 2 HBV drug study By Investing.com - Investing.com Australia
Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection - The Manila Times
Aligos Therapeutics shares fall 2.35% premarket after dosing initiated in Phase 2 B-SUPREME study. - AInvest
Aligos begins dosing in phase 2 HBV drug study - Investing.com
Aligos Therapeutics Initiates Dosing in Phase 2 B-SUPREME Study for Chronic Hepatitis B Virus Infection - Quiver Quantitative
Aligos Begins Major Phase 2 Study Testing Potential Best-in-Class Hepatitis B Drug - Stock Titan
Aligos Therapeutics Inc. stock outlook for YEARJuly 2025 PreEarnings & Long-Term Capital Growth Strategies - Newser
News impact scoring models applied to Aligos Therapeutics Inc.Near-Term Market Opportunity Forecast Sheet - Newser
Smart tools for monitoring Aligos Therapeutics Inc.’s price actionShort Term Momentum Based Trading Strategy - Newser
Is it too late to sell Aligos Therapeutics Inc.Weekly Market Summary & Stock Market Timing Techniques - Newser
Will Aligos Therapeutics Inc. price bounce be sustainableFree Low Capital High Return Stock Plans - Newser
Can ALGS sustain its earnings growth beyond 2024? - AInvest
What's behind ALGS' volatile quarterly earnings? - AInvest
Ranking Aligos Therapeutics Inc. among high performing stocks via toolsFree AI-Powered Trade Planning with Indicators - Newser
Using Bollinger Bands to evaluate Aligos Therapeutics Inc.Weekly High Conviction Trade Setup Analysis - Newser
Aligos Therapeutics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
What explains ALGS' consistent earnings surprises? - AInvest
Will Aligos Therapeutics Inc. stock go up soonExpert-Backed High Yield Stock Watchlist - Newser
Is Aligos Therapeutics Inc. showing signs of accumulationConsistent Gain Plan with AI Support - Newser
Aligos Therapeutics Inc (ALGS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.34%
1.59%
자본화:
|
볼륨(24시간):